Sonoma Pharmaceuticals (NASDAQ: SNOA) files updated investor deck

Rhea-AI Filing Summary

Sonoma Pharmaceuticals, Inc. filed a Form 8-K to provide an updated investor presentation, furnished as Exhibit 99.1 and dated January 12, 2026. The presentation is intended to update investors on the company and its affiliates.

The filing emphasizes that any statements about commercial and technology progress and future financial performance are forward-looking and subject to significant risks and uncertainties. These include potential changes in regulatory or clinical guidelines, the possibility that scientific or clinical data may not meet regulatory standards or be replicated in real-world settings, challenges to the company’s patent protection, and markets that may be smaller or less accessible than expected. The company also cites risks related to revenue sufficiency, foreign currency fluctuations, global economic conditions, tariffs or trade policy changes, and differing regulatory and marketing requirements across countries and municipalities.

false 0001367083 0001367083 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 12, 2026

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-33216		68-0423298
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

5445 Conestoga Court, Suite 150

Boulder, CO 80301

(Address of principal executive offices)

(Zip Code)

(800) 759-9305

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock	SNOA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the “Company”). The presentation materials are filed hereto as Exhibit 99.1.

Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company.

These forward-looking statements are identified by the use of words such as “will,” “develop,” “project,” “expect,” and “expand,” among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number		Description
99.1		Investor Presentation as of January 12, 2026.
104		Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SONOMA PHARMACEUTICALS, INC.
Date: January 12, 2026	By:	/s/ Amy Trombly
	Name: Title:	Amy Trombly Chief Executive Officer

3

FAQ

What did Sonoma Pharmaceuticals (SNOA) report in its latest Form 8-K?

Sonoma Pharmaceuticals filed a Form 8-K to furnish an updated investor presentation for the company and its affiliates, which is attached as Exhibit 99.1 and dated January 12, 2026.

What is included in Sonoma Pharmaceuticals' updated investor presentation?

The updated investor presentation, filed as Exhibit 99.1, is intended to provide information about Sonoma Pharmaceuticals and its affiliates, including commercial and technology progress and future financial performance, as referenced in the forward-looking statements section.

What forward-looking statements does Sonoma Pharmaceuticals highlight in this filing?

The filing notes that forward-looking statements relate to the company’s commercial and technology progress and future financial performance, and are identified by words such as “will,” “develop,” “project,” “expect,” and “expand.”

What key risks and uncertainties does Sonoma Pharmaceuticals describe?

The company cites risks that regulatory or clinical developments may change, data may not meet regulatory standards, clinical results may not be replicated, patents may be challenged or circumvented, markets may be smaller than expected, products may not penetrate targeted markets, and revenues may not meet cash needs.

What external factors does Sonoma Pharmaceuticals say could impact its results?

The filing mentions uncertainties related to foreign currency exchange rate fluctuations, global economic conditions, prospective tariffs or trade policy changes, varying product formulations, and diverse regulatory and marketing requirements in different countries and municipalities.

Does Sonoma Pharmaceuticals commit to updating its forward-looking statements?

The company states that it disclaims any obligation to update its forward-looking statements, except as required by law.